Shares of Prima BioMed Ltd (NASDAQ:IMMP – Get Free Report) have been given an average rating of “Hold” by the five research firms that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, two have given a hold rating, one has issued a buy rating and one has issued a strong buy rating on the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $110.00.
A number of research firms have recently commented on IMMP. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Prima BioMed in a report on Tuesday, October 6th. Jefferies Financial Group raised shares of Prima BioMed from a “hold” rating to a “strong-buy” rating in a research note on Monday, September 14th.
Get Our Latest Stock Analysis on Prima BioMed
Prima BioMed Trading Down 8.8%
IMMP opened at $2.69 on Friday. Prima BioMed has a fifty-two week low of $2.66 and a fifty-two week high of $70.60. The firm’s fifty day moving average price is $4.88 and its two-hundred day moving average price is $16.33.
Prima BioMed (NASDAQ:IMMP – Get Free Report) last announced its quarterly earnings results on Thursday, July 30th. The biotechnology company reported ($1.80) earnings per share (EPS) for the quarter. The business had revenue of $3.68 million for the quarter.
Prima BioMed Company Profile
Prima BioMed Limited was an Australian biotechnology company focused on developing immunotherapies for cancer and other serious diseases. The company’s research centered on treatments designed to activate or enhance the body’s immune response against tumors.
Its principal product candidate was IMP321, also known as eftilagimod alpha, a soluble LAG-3 protein intended to stimulate antigen-presenting cells and support T-cell activity. Prima BioMed evaluated the therapy in combination with other cancer treatments, including chemotherapy and immune checkpoint inhibitors, across several solid-tumor indications.
Prima BioMed later changed its name to Immutep Limited.
See Also
- Five stocks we like better than Prima BioMed
- Google’s Credit Backstop May Be TeraWulf’s Biggest Advantage
- Could the Midterms Revive Medicare for All? 3 Healthcare Stocks to Watch
- Qualcomm Beat Earnings, But Its Fastest-Growing Businesses Have a Catch
- Oil, Uranium, or Renewables? 3 Energy Plays for a Changing Market
Receive News & Ratings for Prima BioMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prima BioMed and related companies with MarketBeat.com's FREE daily email newsletter.
